Company Overview
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company dedicated to transforming patient outcomes in cardiovascular disease through monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The firm functions within the Healthcare sector, specifically serving the Medical Instruments & Supplies industry, where it develops specialized solutions to address complex cardiac conditions. This entity maintains a significant scale with a market capitalization of $1.21B, an annual revenue of $83.72M, and an employee base of 330 individuals. These valuation and revenue figures indicate that the company holds a substantial position in the market relative to its workforce size, suggesting a high valuation multiple that reflects investor expectations for future expansion rather than current profitability.
Financial Health
The company reported revenue of $83.72M for the trailing twelve months, yet it recorded a net income of -$148,120,992 and an EBITDA of -$135,388,992, revealing a cost structure where expenses significantly exceed operating revenues. The gap between the $83.72M in revenue and the -$148,120,992 in net income highlights that the business is currently operating at a substantial loss, implying that cost-cutting measures or revenue growth alone are insufficient to cover the high fixed costs associated with R&D and operations. Free cash flow stands at -$74,894,376, indicating that the company is burning cash and lacks the immediate financial flexibility to fund growth internally without external capital raises. The gross margin is 48.8%, which suggests a healthy ability to price products relative to the cost of goods sold, yet this is offset by an operating margin of -141.6% and a profit margin of -173.0%, demonstrating that overhead and operating expenses are driving the bottom line deeply into negative territory. On the balance sheet, the company holds $291.32M in cash against $46.55M in debt, resulting in a debt-to-equity ratio of 16.16, which indicates a leveraged position where equity is small relative to debt obligations, though the high cash buffer provides a safety net. The current ratio of 7.32 indicates strong short-term liquidity, meaning the company possesses ample liquid assets to cover its short-term liabilities without immediate distress. Return on Equity is -92.7% and Return on Assets is -36.8%, metrics that reveal that management is currently destroying value per share and per asset dollar, a typical characteristic of a growth-stage biotech firm that has not yet achieved commercial profitability.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -9.67, implying that the market prices the stock based on anticipated future earnings rather than current performance. The price-to-book ratio is 4.19, indicating that the market values the company at a significant premium over its net asset book value, reflecting high expectations for the potential of its intellectual property and pipeline. The price-to-sales ratio is 14.43 and the EV/EBITDA is -7.12, suggesting that investors are willing to pay a high multiple for revenue growth despite the lack of earnings power and negative enterprise value relative to EBITDA. The 52-week high is $30.00 and the 52-week low is $13.25, and while the exact current price is not provided in the facts, the valuation metrics suggest the stock trades at a level that reflects its speculative nature and distance from breakeven. The beta is N/A, meaning that specific volatility data relative to the broader market is not available in the provided dataset, so the stock's price sensitivity to market movements cannot be quantified with the available numbers.
Growth & Income
Revenue growth over the year-over-year period is 62.7%, while earnings growth is N/A due to the company's negative earnings history, which implies that revenue expansion is currently decoupled from profitability and that the path to positive earnings remains uncertain. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that it reinvests all available capital and retained earnings back into research, development, and commercialization efforts rather than distributing cash to shareholders. This zero payout ratio is sustainable in the context of a loss-making company that prioritizes growth capitalization over shareholder income distribution. The overall growth and income profile is characterized by robust double-digit revenue expansion but a complete lack of income generation or dividend distribution, positioning the stock as a high-risk, high-potential growth play rather than an income investment.